WGS Uncovers KMT2A PTD, Surpassing Old AML Tests
Detection of KMT2A partial tandem duplication (PTD) in AML by whole genome sequencing (WGS): Addressing limitations of traditional techniques in the era of revumenib approval - Huether et al. #ASCO25 Abst 6532 https://t.co/EEsXm7JGdv #AMLsm #leusm #PrecisionMedicine @TempusAI
First Tumor NGS Usage Varies Across Top Five Cancers
Utilization and timing of first tumor next-generation sequencing testing (NGS) in Pts w/ 5 most common cancers in the USA - @chadihcmd et al. @huntsmancancer #ASCO25 Abstract 11014 https://t.co/lWefncnTb2 #PrecisionMedicine #hemonc #bcsm #crcsm #lcsm #pancsm #pcsm https://t.co/oIX8QTRD8x
Biology’s Data Gap: Making Lab Results AI-Ready
Biology generates enormous amounts of data. Almost none of it is ready for AI. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ1GbK Most experimental infrastructure was built for individual...
Nurix's NRX-0305 Shows
New degrader from Nurix looks interesting: NRX-0305 demonstrated antitumour activity across a wide range of Class 1 BRAF inhibitor-resistant and Class 2/3 mutant PDX models #aacr26 https://t.co/0UGF5Od2Cp
First Personalized CAR‑T Shows Mobility Gains in Stiff Person Syndrome
$KYTX Kyverna Therapeutics cell therapy improves mobility in patients with stiff person syndrome. If cleared, the medicine would be first personalized CAR-T therapy for an autoimmune disease https://t.co/B28Zp9IA2O
Daraxonrasib Monotherapy
Eileen O’Reilly’s daraxonrasib monoTx data in 1L PDAC - poster below to save y’all fighting through rows of people to get a view #aacr26 https://t.co/z4yW2apCBf
Avacta Unveils FAP‑cleavable Dual TOPO‑Ii/DDR‑i Payload
Intriguing #AACR26 poster from Avacta w/ CSO Francis Wilson presenting on their dual payload tech. The idea is to release TOPO-Ii + DDRi via FAP cleavage https://t.co/UMeB8y8KaC
ARVN KRAS G12D Preclinical Shows Weak Tumor Inhibition
In the battle of the inhibitors vs glues vs degraders, this one (KRAS G12D preclinical) from ARVN doesn't look too encouraging with little TGI #aacr26 https://t.co/Ng9UWTQcsv
Aging Mechanisms Are Now Engineerable, Says SynBioBeta
Aging isn't just inevitable decline. It's a set of biological systems that are starting to look engineerable. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ1GbK DNA damage accumulates. Protein...
World's First Longevity Board Launched to Accelerate Aging Therapies
I am very happy to report that we formed the world's first Longevity Board at the public biotechnology company. Our objective is to discover and develop longevity therapeutics with pipeline-in-a-product potential. GLP-1 therapeutics paved the way and demonstrated the path...
Lilly's Retatrutide Achieves 28.7% Weight Loss, Higher Dropouts
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial Lilly is investigating retatrutide in seven other Phase III trials, which are due to read out in 2026. 👨🏻⚕️“Discontinuation rates due to adverse events were 12.2% and 18.2% with retatrutide...
Monoclonal Antibodies Boost Fight Against Infectious Diseases
This is a great conversation w @Invivyd chairman and @politico today on why monoclonal antibodies will enhance our war against infectious diseases.
LLMs Beat JEPA World Models on Sparse Biological Data
Sci-JEPA's and Biology: I'm testing & training LeCunn style JEPA's @SciRouterAI vs more classical Dual encoder LLMs (small 35k data sets) for novel molecule targets for disease quick scans. What's interesting is that even though world models have, in theory, powerful...
Justin Rebo's KindBio Grows Organs On Demand
The Man Growing Organs On Demand Justin Rebo, KindBio and their fantastic sacks 🔗https://t.co/ed4bZbZV0T @Justin_Rebo https://t.co/nCffjjaqJH
Beyond CAR T: Programmable Immune Cells Shaping Future Therapies
CAR T cells cured patients who had no other options. That was just the opening move. #SynBioBeta2026 is May 4-7th in San Jose, California, you can learn more about the conference and get your tickets here: https://t.co/8abYWJ1GbK The next generation of T...
Daraxonrasib Beats Chemo in Pre‑treated Metastatic Pancreatic Cancer
#ASCO26 LBA5 - Wolpin - Daraxonrasib RAS(ON) multi-selective inhibitor vs chemo in prior Tx metastatic pancreatic adenocarcinoma (mPDAC) - Ph3 RASolute 302 [May 31, 2026] https://t.co/oWEeVo2oyq #NCT06625320 #pancsm #caxtx #PrecisionMedicine https://t.co/adz922fg5z
Ivonescimab Plus Chemo Rivals Tislelizumab in First‑line sqNSCLC
#ASCO26 LBA4 - Zhiwei - Ivonescimab + chemo vs tislelizumab + chemo 1L sq NSCLC - Ph3 HARMONi-6 [May 31, 2026] Zhiwei et al. https://t.co/oWEeVo2oyq #NCT05840016 #lcsm #ImmunoOnc https://t.co/NP2qr2gPuY
Adjuvant Selpercatinib Shows Promise
#ASCO26 LBA3 - Goldman - EFS w/ adjuvant sepercatinib in stage IB-IIIA RET fusion-positive NSCLC: Ph3 LIRETTO-432 trial https://t.co/oWEeVo2oyq #NCT04819100 #lcsm #PrecisionMedicine https://t.co/HWIS9mg57w
Phase 3 Trial Shows Abemaciclib Benefits Advanced Liposarcoma
#ASCO26 LBA2 - Dickson -SARC041: Ph3 DBRCT abemaciclib vs placebo in Pts w/ adv dedifferentiated liposarcoma [May 31, 2026] https://t.co/oWEeVo2oyq #NCT04967521 #scmsm https://t.co/uD6A9JmBCn
Genomic Profiling Boosts Survival for Advanced Sarcoma Patients
Using Tumor Genomic Profiling to Guide Treatment Selection Extends Survival in Advanced Sarcoma [May 10, 2019] @ASCO Daily News #scmsm #PrecisionMedicine https://t.co/8625ixTvQu
Perioperative
#ASCO26 LBA1 - Taplin - Perioperative APA + ADT - prostate CA [May 31, 2026] https://t.co/oWEeVo2oyq #NCT03767244 #pcsm https://t.co/8o91ntAwL9
Two Decades of Evolving ASCO Clinical Trial Trends
Trends and characteristics of clinical trials presented in ASCO plenary sessions (2011–2025) [] Overheu #ASCO26 Abstract # 11024, Poster Bd # 7 https://t.co/JYI0LY7FbU #ClinicalTrials #ctsm @ASCO
Labor Dept Demands PBM Payment Transparency Amid Legal Pushback
The Labor Department wants pharmacy benefit managers to disclose, for the first time, all the different ways they get paid. PBMs are warning this proposal is illegal. Supporters want the proposal to go further. The black box of Rx prices...
Scientists Save Billions; CRISPR Cures Sickle Cell
You live in luxury. Without scientists, 6 billion of us would not be alive & the rest would live in hell. Remember that Great choices @brkthroughprize 🏆 Congrats to my colleague @Harvard, Stu Orkin, who won the prize for helping cure...
WGS Uncovers Clinically Relevant Findings Missed in MDS
Whole genome sequencing [WGS] to identify novel, clinically relevant findings missed by standard of care for Pts w/ myelodysplastic syndrome [MDS] - @AlexBataller etal @garciamanero @UTMDAnderson @TempusAI #ASCO26 abst 6570 Pst 363 https://t.co/t7aNW89eRL #MDSsm #leusm #cagenome
First Trial Shows Best‑in‑Class NLRP3 Inhibitor Promise
Excited to complete our first clinical trial for BGE-102. Clinical data supporting best-in-class potential, built on new chemistry and a novel binding site targeting NLRP3 - a central driver of of chronic inflammation in aging. On to Phase 2!
AQUARIUS Registry Uncovers Biomarkers in Blood Cancers
AQUARIUS: A longitudinal multi-center molecular biomarker discovery registry for Pts w/ hematologic malignancies - @mtmdphd et al. @TempusAI & IFLI - Instit Follicular Lymphoma Innovation #ASCO26 abstr TPS7105, Poster 599a https://t.co/70G0v1P968 #NCT07154823 #lymsm #cagenome
AI Can Streamline Drug Approval, Boost Biotech Valuations
That is an interesting idea. This doesn't seem catered to investors per se, but with two partners in the summer of 25, we explored building an “AI-powered AlphaSense for biopharma” ultimately concluding it was too much work to do as...
ASCO26 Unveils Pancreatic
#ASCO26 abstract titles were released today: $RVMD RASolute Ph3 study in pancreatic cancer will be presented during the plenary session. Also, Akeso $SMMT ivonescimab HARMONi-6 trial in lung cancer. China-only data.
BioAge's Inflammation Drug Shows Best‑in‑class Promise
BioAge says early data suggest ‘best-in-class’ potential for inflammation drug https://t.co/D2owlYxCRa by Kristin Jensen $BIOA $LLY $NMRA
SMMT Spikes as Akeso OS Data Lands Plenary
Summit Thera. $SMMT Well… that answers that. SMMT shares initially popped (as much as ~15%) on today’s release of ASCO abstract titles with the unexpected news that the much-anticipated OS data from Akeso’s HARMONi-6 will be released in a Plenary slot...
MRNA Brand Stigmatized by COVID Vaccine Backlash, Says Bhattacharya
That is literally a lie, as Bhattacharya wrote an op-ed trying to explain their move. He essentially was arguing that the "brand" of mRNA is tainted by public backlash to the COVID vaccine. https://t.co/5KXQJtCCxM https://t.co/HDQRvQK0ki
Promising Mufemilast Results Unveiled at DDW
Strong mufemilast data being presented at DDW this week for anyone still following the $PALI story. https://t.co/Oi4WI6R0iW
AI Accelerates Small Molecule Synthesis, Says Martin Burke
Small molecule synthesis made faster for the AI era: Listen to Martin Burke on The Long Run. Sponsors: @AlphaSenseInc and Dash Bio. https://t.co/D990phgzg8
Research Shows Nicotine May Boost Cognition, Guard Against Parkinson's
The New York Times mentioned me in an article about nicotine. They're skeptical. Here's what they didn't include... Dr. Paul Newhouse at Vanderbilt ran controlled trials showing nicotine improved concentration and cognitive function in people with mild cognitive impairment. Peer-reviewed, published...
Regulatory Hurdles, Not Tech, Slow Biotech Breakthroughs
"We need 6 'AlphaFold' moments to compress the drug delivery timeline from 10yrs to a few months" -Demis Yes and the FDA will still take 10yrs to approve it. Safetyism has throttled biotech unnecessarily and the only way to accelerate is to...
Tortugas Neuroscience Launches to Develop Brain Disorder Drugs
Tortugas Neuroscience launches with hopes to develop drugs for brain disorders, other conditions https://t.co/zoM69VEQtV via @ADeAngelis_bio
Trump Order Boosts Psychedelic Biotech Stocks
Trump executive order lifts psychedelics biotechs https://t.co/3H00cxuF4A by @realJacobBell $GHRS $HRELP $DFTX $ENVB $COMP $ATAI #biotech
Serif Targets Revolutionary Genetic Medicine Platform
Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine https://t.co/kvmbF3xYKu by @gwendolynawu #biotech #startups @FlagshipPioneer
Celastrol Disrupts Hsc70‑Bim to Boost Longevity, Reduce Fibrosis
Celastrol Targets Hsc70-Bim Interaction as a Novel Senolytic to Extend Lifespan and Mitigate Organ Fibrosis https://t.co/Iv51QlhH5l
Long‑time Applicants Finally See Chance for Rigorous Testing
Been applying to her office and others (eg welcome trust, nimh, arpa) for years asking to test/demonstrate that this isn’t magical thinking or snake oil. Glad to see things might change.
Four Overlooked AACR Early-Stage Agents Worth Watching
While everyone was watching KRAS, some of AACR’s promising early stage pipeline agents were easy to miss. Here's an analysis on four examples which caught my eye and are well worth watching to see how they develop in the...
New RAS Cancer Drugs Aim to Beat RevMedicines’ Success
April20: Which RAS-based cancer drug developers are working to improve upon the dazzling pancreatic cancer results of @RevMedicines' daraxonrasib, whose stock surged 54%? Read about $RVMD plus updates on $MGTX and $TVTX in my latest StockWatch for @GENbio: https://t.co/9wQA7XsuLW
Tenofovir Alafenamide Cuts Biological Age in Adults
An FDA-Approved Tenofovir Alafenamide-Based Antiretroviral Therapy Reduces Biological Age in Healthy Adults: First Human Proof-of-Concept for Retrotransposon-Targeted Gerotherapeutics 💫 https://t.co/FFvTmJv2zv https://t.co/DHHQ18nAmy
Epigenome Proteins Enable Precise Cellular Engineering Beyond On/Off Control
Epigenome proteins generate distinct gene expression patterns, influencing cellular behavior beyond simple on/off control and offering new avenues for precise cellular engineering. generegulation
HDAC7 Loss Predicts Poor DLBCL Outcomes; Restoration Stops Tumor
Loss of the HDAC7 protein in diffuse large B cell lymphoma is linked to poorer outcomes, while restoring HDAC7 in cancer cells halts tumor growth, highlighting its potential as both a biomarker and therapeutic target. bloodcancer
Gene Therapy Works Best for Deaf Children Aged 5‑8
AAV gene therapy for autosomal recessive deafness 9: a single-arm trial 🌟“Gene therapy for congenital deafness has shown promising results in children but lacks data in older populations… . An age-dependent therapeutic effect was observed, with optimal outcomes in 5- to...
Promising Longevity Molecule Stalled by Misaligned Incentives
The Longevity Drug You’ve Never Heard Of This is one of those stories that captures both the promise—and the frustration—of longevity science. In this preview episode, Dr. George Sutphin (@senmorteco ), Associate Professor of Molecular and Cellular Biology at the @uarizona @UAZCancer , walks...
Anktiva Needs Trial Data Before FDA Approval
For the umpteenth time, these posters have zero relevance to Anktiva unless, or until, $IBRX conducts/completes randomized clinical trials that demonstrate the drug improves outcomes for cancer patients w/ lymphopenia. @LoriMills4CA42 and the rest of you can idolize @DrPatrick ...
Formulary Rules Favor Costlier Drug, Creating Unnecessary Hassle
So I need to take esomeprazole (Nexium) instead of omeprazole (Prilosec). They are both generic - at @costplusdrugs they cost $5.86 and $6.34 respectively (so the eso version is actually cheaper). But on the Blue Cross Medicare formulary, they only...